Alan Henry Raffensperger

Director/Board Member chez SPAGO NANOMEDICAL AB

Profil

Alan Henry Raffensperger is currently the Chief Executive Officer at Swedemed Ab and a Director at Masimo Sweden AB, Spago Nanomedical AB, Rolf Lufts Stiftelse Foer Diabetesforskning, and Inceptua Ltd.
He previously served as the Chief Executive Officer at BeneChill, Inc., Inceptua SA, and Swedish Orphan Biovitrum AB.
He was also the Chairman at Palette Life Sciences AB and held various director positions at Roche Pharmaceuticals, Inc., Roche Diagnostics GmbH, and Metracor Technologies, Inc. Additionally, he was the Executive Director & Head-Nephrology at Amgen International AG.
Raffensperger holds an MBA from George Washington University, an undergraduate degree from the University of Maryland, and a doctorate from the University of Minnesota.

Postes actifs de Alan Henry Raffensperger

Sociétés	Poste	Début
SPAGO NANOMEDICAL AB	Director/Board Member	10/05/2023
Inceptua Ltd.	Director/Board Member	17/10/2018
Masimo Sweden AB	Director/Board Member	-
Swedemed Ab	Chief Executive Officer	12/08/2011
Rolf Lufts Stiftelse Foer Diabetesforskning	Director/Board Member	-

Anciens postes connus de Alan Henry Raffensperger

Sociétés	Poste	Fin
XVIVO PERFUSION AB	Director/Board Member	01/04/2020
SWEDISH ORPHAN BIOVITRUM AB	Chief Operating Officer	07/06/2017
BeneChill, Inc.	Chief Executive Officer	01/01/2012
Amgen International AG	Director/Board Member	01/01/2010
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░	░░░░░ ░ ░░░░░░░░░	░░░░░░░░░░

Formation de Alan Henry Raffensperger

George Washington University	Masters Business Admin
University of Maryland	Undergraduate Degree
University of Minnesota	Doctorate Degree